Study summary
Engineered T cells shrank tumors in about 4 in 10 people with advanced synovial sarcoma
39%response rate in synovial sarcoma
What was tested
Afamitresgene autoleucel (afami-cel), a one-time infusion of a patient's own T cells engineered to recognize the MAGE-A4 protein, for advanced synovial sarcoma or myxoid round cell liposarcoma after chemotherapy.
What they found
- Tumors shrank in 39% of people with synovial sarcoma and 25% with myxoid round cell liposarcoma.
- Cytokine release syndrome occurred in 71%, almost all mild.
- People had a median of three earlier treatments.
What it means
The first engineered T-cell therapy approved for any solid tumor. Only for people with a specific immune type (HLA-A*02) whose tumors express MAGE-A4.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.